RxDoctor Payments Data

Shanna May, OD

Optometrist · Troy, ALNPI 1487622932

Payments from drug & device makers

$1,434in general payments, 2019–2025

Across 59 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$302
  • Johnson & Johnson Vision Care, Inc.$277
  • Kala Pharmaceuticals, Inc.$235
  • Biotissue Holdings Inc.$121
  • Novartis$94
  • Alcon$73
  • plus $332 from 9 others

What the payments were for

  • Food & beverage$1,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,434 in reported general payments places this provider in the 60th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$21,775
Medicare patients
99
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine50$49,066
Cyclosporine33$21,549
XiidraLifitegrast18$16,127
LumiganBimatoprost24$9,652
VyzultaLatanoprostene Bunod24$7,834
CequaCyclosporine12$6,854
Latanoprost99$1,530
Travoprost19$1,158
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat52$932
Brimonidine Tartrate26$660
Dorzolamide Hcl24$638
Timolol Maleate17$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$18$58,71874 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$68$23,96142 claims
Sun Pharmaceutical Industries Inc.Cequa$302$6,85412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 749 optometrist providers in Alabama.

Other optometrist in Troy

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →